SAB Biotherapeutics Inc (SABS)
2.97
+0.01
(+0.34%)
USD |
NASDAQ |
Jun 25, 16:00
2.97
0.00 (0.00%)
After-Hours: 20:00
SAB Biotherapeutics Enterprise Value: -16.09M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | -16.09M |
| June 24, 2024 | -15.90M |
| June 21, 2024 | -17.01M |
| June 20, 2024 | -17.66M |
| June 18, 2024 | -19.41M |
| June 17, 2024 | -13.23M |
| June 14, 2024 | -14.15M |
| June 13, 2024 | -13.41M |
| June 12, 2024 | -12.76M |
| June 11, 2024 | -11.93M |
| June 10, 2024 | -12.58M |
| June 07, 2024 | -16.05M |
| June 06, 2024 | -17.01M |
| June 05, 2024 | -18.02M |
| June 04, 2024 | -18.39M |
| June 03, 2024 | -18.58M |
| May 31, 2024 | -18.86M |
| May 30, 2024 | -18.86M |
| May 29, 2024 | -17.20M |
| May 28, 2024 | -18.12M |
| May 24, 2024 | -18.12M |
| May 23, 2024 | -19.32M |
| May 22, 2024 | -17.01M |
| May 21, 2024 | -16.36M |
| May 20, 2024 | -11.38M |
| Date | Value |
|---|---|
| May 17, 2024 | -9.719M |
| May 16, 2024 | -7.504M |
| May 15, 2024 | -6.304M |
| May 14, 2024 | -5.889M |
| May 13, 2024 | -5.474M |
| May 10, 2024 | -6.212M |
| May 09, 2024 | -6.304M |
| May 08, 2024 | -5.382M |
| May 07, 2024 | -5.474M |
| May 06, 2024 | -6.858M |
| May 03, 2024 | -6.028M |
| May 02, 2024 | -6.120M |
| May 01, 2024 | -5.382M |
| April 30, 2024 | -3.628M |
| April 29, 2024 | -4.551M |
| April 26, 2024 | -3.998M |
| April 25, 2024 | -6.212M |
| April 24, 2024 | -2.613M |
| April 23, 2024 | -2.982M |
| April 22, 2024 | -2.705M |
| April 19, 2024 | -3.628M |
| April 18, 2024 | -2.059M |
| April 17, 2024 | -0.7668M |
| April 16, 2024 | 1.817M |
| April 15, 2024 | -0.6745M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-19.41M
Minimum
Jun 18 2024
487.99M
Maximum
Dec 01 2021
67.14M
Average
33.13M
Median
Aug 11 2023
Enterprise Value Benchmarks
| CEL-SCI Corp | 61.31M |
| AIM ImmunoTech Inc | 11.80M |
| IGC Pharma Inc | 31.39M |
| NovaBay Pharmaceuticals Inc | 2.939M |
| Protalix BioTherapeutics Inc | 66.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.026M |
| Total Expenses (Quarterly) | 11.39M |
| EPS Diluted (Quarterly) | -0.54 |
| Earnings Yield | -230.6% |